Akso Health Group ADR (AHG)vsEli Lilly and Company (LLY)
AHG
Akso Health Group ADR
$0.84
+14.93%
HEALTHCARE · Cap: $625.57M
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 575859% more annual revenue ($79.67B vs $13.83M). LLY leads profitability with a 33.5% profit margin vs -135.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
AHG
Avoid15
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.2%
Fair Value
$1.57
Current Price
$0.84
$0.73 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -89.4% — below average capital efficiency
Revenue declined 12.9%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AHG
The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : AHG
The primary concerns for AHG are EPS Growth, Market Cap, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
AHG profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 15/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akso Health Group ADR
HEALTHCARE · MEDICAL DISTRIBUTION · China
Akso Health Group ADR is a leading entity in the healthcare sector, dedicated to providing innovative medical solutions and comprehensive patient care services. With a strong emphasis on advanced health technologies, the company is strategically positioned in the telehealth and personalized medicine markets, supported by a robust research and development framework. As it navigates the rapidly evolving healthcare landscape, Akso Health Group presents an attractive investment opportunity for institutional investors seeking to capitalize on transformative trends within the industry.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?